Gemmer Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-203
| Closed | -$4K | – | 1485 |
|
|
2018
Q1 | $4K | Hold |
203
| – | – | ﹤0.01% | 1129 |
|
|
2017
Q4 | $3K | Hold |
203
| – | – | ﹤0.01% | 1173 |
|
|
2017
Q3 | $4K | Hold |
203
| – | – | ﹤0.01% | 1078 |
|
|
2017
Q2 | $3K | Buy |
+203
| New | +$3K | ﹤0.01% | 1169 |
|
|
2017
Q1 | – | Sell |
-166
| Closed | -$2K | – | 1267 |
|
|
2016
Q4 | $2K | Sell |
166
-83
| -33% | -$1.42K | ﹤0.01% | 1182 |
|
|
2016
Q3 | $6K | Buy |
249
+43
| +21% | +$1.16K | ﹤0.01% | 864 |
|
|
2016
Q2 | $6K | Buy |
206
+34
| +20% | +$1.11K | ﹤0.01% | 833 |
|
|
2016
Q1 | $5K | Hold |
172
| – | – | ﹤0.01% | 856 |
|
|
2015
Q4 | $7K | Hold |
172
| – | – | ﹤0.01% | 736 |
|
|
2015
Q3 | $6K | Hold |
172
| – | – | ﹤0.01% | 778 |
|
|
2015
Q2 | $8K | Sell |
172
-7
| -4% | -$332 | ﹤0.01% | 675 |
|
|
2015
Q1 | $8K | Buy |
179
+7
| +4% | +$279 | ﹤0.01% | 738 |
|
|
2014
Q4 | $5K | Sell |
172
-31
| -15% | -$907 | ﹤0.01% | 898 |
|
|
2014
Q3 | $5K | Buy |
203
+21
| +12% | +$538 | ﹤0.01% | 903 |
|
|
2014
Q2 | $5K | Hold |
182
| – | – | ﹤0.01% | 948 |
|
|
2014
Q1 | $5K | Buy |
+182
| New | +$4.55K | ﹤0.01% | 921 |
|
Gemmer Asset Management's IPXL Position: Q2 2018 in Review
Gemmer Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 203 shares — an estimated $4K sold.
Gemmer Asset Management first reported a position in IPXL in Q1 2014 and held it in 16 quarters. The position peaked at $8K in Q2 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Gemmer Asset Management reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Gemmer Asset Management sold 203 Impax Laboratories, Inc. shares in Q2 2018, an estimated $4K.
- Gemmer Asset Management first reported a position in Impax Laboratories, Inc. in Q1 2014 and held it in 16 quarters.
- Gemmer Asset Management's Impax Laboratories, Inc. position peaked at $8K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Gemmer Asset Management's 13F filing for Q2 2018, filed 18 Jul 2018.